DK541889D0 - Virus-modificerede tumorvacciner til immunterapi af tumormetastaser - Google Patents

Virus-modificerede tumorvacciner til immunterapi af tumormetastaser

Info

Publication number
DK541889D0
DK541889D0 DK541889A DK541889A DK541889D0 DK 541889 D0 DK541889 D0 DK 541889D0 DK 541889 A DK541889 A DK 541889A DK 541889 A DK541889 A DK 541889A DK 541889 D0 DK541889 D0 DK 541889D0
Authority
DK
Denmark
Prior art keywords
pct
virus
tumor
immunery
modified
Prior art date
Application number
DK541889A
Other languages
Danish (da)
English (en)
Other versions
DK541889A (da
Inventor
Volker Schirrmacher
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK541889(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of DK541889A publication Critical patent/DK541889A/da
Publication of DK541889D0 publication Critical patent/DK541889D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK541889A 1988-03-01 1989-10-31 Virus-modificerede tumorvacciner til immunterapi af tumormetastaser DK541889D0 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
PCT/EP1989/000186 WO1989007946A1 (fr) 1988-03-01 1989-02-27 Vaccins tumoraux modifies viralement pour immunotherapie de metastases tumorales

Publications (2)

Publication Number Publication Date
DK541889A DK541889A (da) 1989-10-31
DK541889D0 true DK541889D0 (da) 1989-10-31

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK541889A DK541889D0 (da) 1988-03-01 1989-10-31 Virus-modificerede tumorvacciner til immunterapi af tumormetastaser

Country Status (10)

Country Link
US (1) US5273745A (enExample)
EP (1) EP0331102B1 (enExample)
JP (1) JPH02504034A (enExample)
KR (1) KR900700130A (enExample)
AT (1) ATE90877T1 (enExample)
AU (1) AU3188989A (enExample)
DE (2) DE3806565A1 (enExample)
DK (1) DK541889D0 (enExample)
ES (1) ES2042828T3 (enExample)
WO (1) WO1989007946A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
WO1993006867A1 (en) * 1991-10-04 1993-04-15 Whitehead Institute For Biomedical Research The regulation of systemic immune responses utilizing cytokines and antigens
EP1314431B1 (en) * 1993-04-30 2008-07-16 Wellstat Biologics Corporation Purified compositions of Newcastle disease virus
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
WO1997042220A1 (en) * 1996-05-03 1997-11-13 Thomas Jefferson University Metastatic colorectal cancer vaccine
PL328790A1 (en) * 1996-10-04 1999-02-15 Univ Jefferson T-lymphocytes provoking an immunological response and methods of using them
ATE284707T1 (de) * 1997-08-22 2005-01-15 Science Park Raf S P A Tumorvakzinierung mittels verwendung autologer oder hla-verwandter antigen präsentierender zellen (apc), die mit einem tumorantigen sowie einem eine immunantwort hervorrufenden fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
AU2006320490A1 (en) 2005-12-02 2007-06-07 The Mount Sinai School Of Medicine Of New York University Chimeric viruses presenting non-native surface proteins and uses thereof
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
WO2010036652A1 (en) * 2008-09-23 2010-04-01 Thomas Jefferson University Cancer vaccines against mucosal antigens and methods of making and using the same
DK2327764T3 (da) 2009-11-30 2012-04-02 United Cancer Res Inst Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
KR102407019B1 (ko) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
KR900700130A (ko) 1990-08-11
US5273745A (en) 1993-12-28
WO1989007946A1 (fr) 1989-09-08
DK541889A (da) 1989-10-31
EP0331102A1 (de) 1989-09-06
DE3806565A1 (de) 1989-09-14
JPH02504034A (ja) 1990-11-22
EP0331102B1 (de) 1993-06-23
DE58904760D1 (de) 1993-07-29
AU3188989A (en) 1989-09-22
ATE90877T1 (de) 1993-07-15
ES2042828T3 (es) 1993-12-16
DE3806565C2 (enExample) 1991-04-25

Similar Documents

Publication Publication Date Title
DK541889D0 (da) Virus-modificerede tumorvacciner til immunterapi af tumormetastaser
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
ATE306939T1 (de) Mehrstufiger kaskade-erhöhungsimpfstoff
DK157087A (da) Multivalent vaccine, isaer herpesvirusvaccine, dens anvendelse og deri indgaaende virus
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
FI823021A7 (fi) Tuotteet, jotka osoittavat hepatitis B virus e antigeenin antigeenisuuden ja menetelmät näiden antigeenien vavalmistamiseksi.
DE3689622D1 (de) Impfstoffe gegen menschliche respiratorische viren.
BR9704879A (pt) Composição de vacina e uso de um vírus cav vivo
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
AR016987A1 (es) Composiciones acuosas de vacuna acuosaa para la profilaxis de hepatitis b o hepatitis b/a
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
KR890006254A (ko) 비-특이적 면역성 인듀서의 제조방법
DK41885A (da) 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
NL300073I1 (nl) Vaccin.
SE8700466D0 (sv) Vaccines against melanoma
ATE166880T1 (de) Impfstoff gegen cholera
IL85266A0 (en) Newcastle disease virus(ndv)vaccine and method for the application thereof

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment